Diabetes Drug Notes

DIABETES DRUG NOTES
 
Diabetes is becoming more common in both older and younger generations and in keeping with this escalation in cases, there are an ever increasing number of drugs and drug classes that are suitable to treat hyperglycaemia. In a unique blend of diabetes practice, clinical pharmacology, and cardiovascular medicine, Diabetes Drug Notes describes the principles of clinical pharmacology with regards to diabetes prescribing. Each drug class for the treatment of diabetes is covered in detail, along with the effect on the cardiovascular and renal systems caused by each drug. Building upon the success of their "Drug Notes" series for Practical Diabetes and their "Drugs for Diabetes" series in the British Journal of Cardiology, the team of experts focuses on the glycaemic management of type 1 and type 2 diabetes, with other effects of antidiabetic drugs covered as well.
 
Diabetes Drug Notes also includes:
* Comprehensive and up-to-date coverage of the drugs for the glycaemic management of patients with type 1 or type 2 diabetes
* Expert reflection on prescribing considerations for special groups, as well as common pitfalls in prescribing
* Detailed case histories to illustrate relevant information
* Summaries of recent guidelines related to diabetic intervention
 
Diabetes Drug Notes is a user-friendly guide for a general diabetes medical, nursing, and pharmacology readership, as well as those who support them.

Sommario

Foreword xx
 
Preface xxi
 
Editors and Contributors xxii
 
Introduction 1
 
1 Clinical Pharmacology of Antidiabetic Drugs 2
Andrea Llano, Gerry McKay, and Ken Paterson
 
Introduction 2
 
Clinical Pharmacology 3
 
Drug Metabolism and Elimination 6
 
Drug Development and Clinical Trials 7
 
Drug Licensing of Antidiabetic Drugs 12
 
Development and Licensing of Insulin 14
 
Development and Approval of Biosimilar Insulin 16
 
Pharmacovigilance 19
 
Pharmacoeconomics 21
 
Future Developments in Diabetes Clinical Pharmacology 26
 
2 Metformin 30
Joseph Timmons and James Boyle
 
Introduction 30
 
Pharmacology 32
 
Mechanism of Action 32
 
Glycaemic Efficacy 36
 
Safety and Side Effects 37
 
Metformin in Type 1 Diabetes 45
 
Place of Metformin in Current and Future Practice 46
 
3 Sulfonylureas and Meglitinides 49
Joseph Timmons and James Boyle
 
Introduction 49
 
Pharmacology 51
 
Glycaemic Efficacy 53
 
Safety and Side Effects 55
 
Outcome Trials 56
 
Meglitinides 61
 
Place of Sulfonylureas and Meglitinides in Current and Future Practice 65
 
4 DPP-4 Inhibitors 67
Sharon Mackin and Gemma Currie
 
Introduction 67
 
Pharmacology 68
 
Glycaemic Efficacy 75
 
Safety and Side Effects 79
 
Outcome Trials 82
 
Renal Outcomes 89
 
The Place of DPP-4 Inhibitors in Current and Future Practice 91
 
5 SGLT2 Inhibitors 95
Miles Fisher, Andrea Llano, and Gerry McKay
 
Introduction 96
 
Pharmacology 96
 
Glycaemic Efficacy 100
 
Side Effects and Safety 103
 
Outcome Trials 105
 
Renal Outcome Trials 110
 
Heart Failure Outcome Trials 116
 
SGLT2 Inhibitors in Type 1 Diabetes 119
 
Use of SGLT2 Inhibitors in Other Diseases 123
 
Dare- 19 123
 
Place of SGLT2 Inhibitors in Current and Future Practice 124
 
6 GLP-1 Receptor Agonists 130
Catherine Russell and John Petrie
 
Introduction 130
 
Pharmacology 131
 
Glycaemic Efficacy and Effect on Weight 137
 
Side Effects and Safety 142
 
Outcome Trials 143
 
Use of GLP-1 Receptor Agonists in Other Diseases 153
 
Place of GLP-1 Receptor Agonists in Current and Future Practice 155
 
7 Animal and Human Insulins 161
Ken Paterson
 
Introduction 161
 
Production and Pharmacokinetic Modifications 165
 
Hypoglycaemia and Human Insulin 170
 
Intensified Insulin Therapy 173
 
Place of Human Insulin in Current and Future Therapy 176
 
8 Short-acting Insulin Analogues 179
Kate Hughes and Gerry McKay
 
Introduction 179
 
Factors Affecting Absorption and Metabolism of Short-acting Insulin 180
 
Manufacturing Insulin Analogues 180
 
Short-acting Insulin Analogues 182
 
Second-generation Ultrafast-acting Insulin Analogues 186
 
Other Attempts to Improve Insulin Absorption and Inhaled Insulin 189
 
Place of Short-acting Insulin Analogues in Current and Future Practice 190
 
9 Long-acting Insulin Analogues 194
Robert Lindsay
 
Introduction 195
 
Development of Long-acting Insulin Analogues 196
 
Long-acting Insulin Analogues 197
 
Meta-analysis of Glycaemic Efficacy of Long-acting Insulin Analogues 207
 
Safety of Long-acting Insulin Analogues 209
 
The Place of Long-acting Insulin Analogues in Current and Future Practice 209
 
10

Info autore

Prof. Miles Fisher is a former Consultant Physician, Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, and an Honorary Professor at the University of Glasgow, UK.
Prof. Gerard A. McKay is a Consultant Physician, Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, an Honorary Clinical Associate Professor, University of Glasgow, as well as a Visiting Professor at the University of Strathclyde, UK. Dr Andrea Llano is a Consultant Physician, Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, and an Honorary Clinical Lecturer, University of Glasgow, UK.

Riassunto

DIABETES DRUG NOTES

Diabetes is becoming more common in both older and younger generations and in keeping with this escalation in cases, there are an ever increasing number of drugs and drug classes that are suitable to treat hyperglycaemia. In a unique blend of diabetes practice, clinical pharmacology, and cardiovascular medicine, Diabetes Drug Notes describes the principles of clinical pharmacology with regards to diabetes prescribing. Each drug class for the treatment of diabetes is covered in detail, along with the effect on the cardiovascular and renal systems caused by each drug. Building upon the success of their "Drug Notes" series for Practical Diabetes and their "Drugs for Diabetes" series in the British Journal of Cardiology, the team of experts focuses on the glycaemic management of type 1 and type 2 diabetes, with other effects of antidiabetic drugs covered as well.

Diabetes Drug Notes also includes:
* Comprehensive and up-to-date coverage of the drugs for the glycaemic management of patients with type 1 or type 2 diabetes
* Expert reflection on prescribing considerations for special groups, as well as common pitfalls in prescribing
* Detailed case histories to illustrate relevant information
* Summaries of recent guidelines related to diabetic intervention

Diabetes Drug Notes is a user-friendly guide for a general diabetes medical, nursing, and pharmacology readership, as well as those who support them.

Dettagli sul prodotto

• Autori: Fisher, M Fisher, Miles Fisher, Miles (Royal Alexandra Hospital Fisher, Miles Mckay Fisher, Andrea Llano, Gerard A. Mckay
• Con la collaborazione di: Gerard A McKay (Editore), Miles Fisher (Editore), Andrea Llano (Editore), Gerard A. Mckay (Editore), McKay Gerard A. (Editore)
• Editore: Wiley, John and Sons Ltd
• Lingue: Inglese
• Formato: Tascabile
• Pubblicazione: 31.07.2022
• EAN: 9781119785002
• ISBN: 978-1-119-78500-2
• Pagine: 400
• Categorie: Guide e manuali > Salute; Scienze naturali, medicina, informatica, tecnica > Medicina > Tematiche generali; Diabetes, Medizin, Pharmakologie, Pharmacology & Pharmaceutical Medicine, Pharmakologie u. Pharmazeutische Medizin, Medical Science, Allg. Medizin